Aprea Therapeutics announces interim results from an ongoing first-in-human Phase 1 study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR.
Aprea Therapeutics announces interim results from an ongoing first-in-human Phase 1 study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in